Chronotherapeutic dosing of medication and medication regimen adherence

Patent metadata

Field	Value
Publication number	US-11039986-B2
Application number	US-201715436916-A
Country	US
Kind code	B2
Filing date	Feb 20, 2017
Priority date	Feb 25, 2016
Publication date	Jun 22, 2021
Grant date	Jun 22, 2021

Abstract

Chronotherapeutic dosing can include receiving, using a processor, sensor data from a sensor for a user, wherein the sensor data is collected subsequent to the user starting a regimen for a medication, determining, using the processor, a biological marker from the sensor data, wherein the biological marker is correlated with the medication, and comparing, using the processor, the biological marker with an expected state of the biological marker based upon a dose time of the medication. Chronotherapeutic dosing can also include providing, using the processor, a notification indicating a result of the comparing.

First claim

What is claimed is:

1. A method of chronotherapeutic dosing, comprising:
generating sensor data corresponding to a user using one or more sensors of a device, wherein the sensor data is generated subsequent to the user starting a regimen for a medication;
detecting, using a processor of the device, dyssynchrony in sleep of the user based on a comparison of a sleep pattern of the user, determined from the sensor data, with a circadian rhythm for sleep;
determining, from a medication database and using the processor, a half-life of the medication, wherein the medication regulates a circadian-based phenomenon;
determining, using the processor, the circadian-based phenomenon for the user from the sensor data, wherein the circadian-based phenomenon is determined from a biological marker including at least one of blood pressure or heart rate;
determining, using the processor, that the circadian-based phenomenon does not occur during the half-life of the medication based on a dose time of the medication for the user, wherein the circadian-based phenomenon is dipping of at least one of heart rate or blood pressure during night;
comparing, using the processor, the circadian-based phenomenon with an expected healthy trend of the circadian-based phenomenon retrieved from a circadian variation database thereby determining a difference between the circadian-based phenomenon and an expected healthy trend, wherein the difference exceeds a threshold and occurs outside of the half-life of the medication; and
in response to detecting the dyssynchrony in sleep of the user and determining the difference, providing, using the processor, a notification of the difference;
wherein the notification is generated to recommend an alternative medication that regulates the biological marker, wherein the alternative medication has a longer half-life than the medication.

2. The method of claim 1 , wherein the circadian-based phenomenon includes morning surge reactivity in the user.

3. A system for chronotherapeutic dosing, comprising:
one or more sensors configured to generate sensor data corresponding to a user, wherein the sensor data is generated by the one or more sensors subsequent to the user starting a regimen for a medication;
a memory storing instructions; and
a processor coupled to the sensor and the memory, wherein the processor, in response to executing the instructions, is configured to initiate executable operations including:
detecting dyssynchrony in sleep of the user based on a comparison of a sleep pattern of the user, determined from the sensor data, with a circadian rhythm for sleep;
determining, from a medication database, a half-life of the medication, wherein the medication regulates a circadian-based phenomenon;
determining the circadian-based phenomenon for the user from the sensor data, wherein the circadian-based phenomenon is determined from a biological marker including at least one of blood pressure or heart rate;
determining, using the processor, that the circadian-based phenomenon does not occur during the half-life of the medication based on a dose time of the medication for the user, wherein the circadian-based phenomenon is dipping of at least one of heart rate or blood pressure during night;
comparing, using the processor, the circadian-based phenomenon with an expected healthy trend of the circadian-based phenomenon retrieved from a circadian variation database thereby determining a difference between the circadian-based phenomenon and an expected healthy trend, wherein the difference exceeds a threshold and occurs outside of the half-life of the medication; and
in response to detecting the dyssynchrony in sleep of the user and determining the difference, providing a notification of the difference;

wherein the processor is configured to generate the notification to recommend an alternative medication that regulates the biological marker, wherein the alternative medication has a longer half-life than the medication.

4. The system of claim 3 , wherein the circadian-based phenomenon includes morning surge reactivity in the user.

5. A computer program product comprising a non-transitory computer readable storage medium having program code stored thereon, the program code executable by a processor to perform operations for chronotherapeutic dosing comprising:
receiving sensor data corresponding to a user, wherein the sensor data is generated by one or more sensors of a device and is generated subsequent to the user starting a regimen for a medication;
detecting dyssynchrony in sleep of the user based on a comparison of a sleep pattern of the user, determined from the sensor data, with a circadian rhythm for sleep;
determining, from a medication database, a half-life of the medication, wherein the medication regulates a circadian-based phenomenon;
determining the circadian-based phenomenon for the user from the sensor data, wherein the circadian-based phenomenon is determined from a biological marker including at least one of blood pressure or heart rate;
determining that the circadian-based phenomenon does not occur during the half-life of the medication based on a dose time of the medication for the user, wherein the circadian-based phenomenon is dipping of at least one of heart rate or blood pressure during night;
comparing the circadian-based phenomenon with an expected healthy trend of the circadian-based phenomenon retrieved from a circadian variation database thereby determining a difference between the circadian-based phenomenon and an expected healthy trend, wherein the difference exceeds a threshold and occurs outside of the half-life of the medication; and
in response to detecting the dyssynchrony in sleep of the user and determining the difference, providing a notification of the difference;
wherein the notification is generated to recommend an alternative medication that regulates the biological marker, wherein the alternative medication has a longer half-life than the medication.

6. The computer program product of claim 5 , wherein the circadian-based phenomenon includes morning surge reactivity in the user.

Assignees

• Samsung Electronics Co Ltd

Inventors

• Jain Jawahar
• Wortham Cody
• Young James
• Sadi Sajid
• Mistry Pranav

Classifications

• A61B5/4833 Primary

  Assessment of subject's compliance to treatment · CPC title

• A61B5/165

  Evaluating the state of mind, e.g. depression, anxiety · CPC title

• A61B5/02108

  from analysis of pulse wave characteristics · CPC title

• A61B5/4806

  Sleep evaluation (A61B5/4821 takes precedence; devices for inducing sleep A61M21/02) · CPC title

• A61B5/1113

  Local tracking of patients, e.g. in a hospital or private home · CPC title